Rani Therapeutics Holdings (RANI) Times Interest Earned (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted Times Interest Earned of 1103.5 for Q2 2026, down 1064.5% on a QoQ basis from 94.76 in Q1 2026, and down 9112.47% year-over-year from 12.24 in Q2 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Times Interest Earned (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Times Interest Earned for 7 years, with the latest figure at 1103.5 in Q2 2026.
- On a quarterly basis, Times Interest Earned fell 9112.47% year-over-year to 1103.5 in Q2 2026; TTM through Jun 2026 was 28.22, a 145.16% decrease from a year earlier, with the FY2025 full-year figure at 13.25, down 25.1% from the prior year.
- Times Interest Earned was 1103.5 for Q2 2026 at Rani Therapeutics Holdings, down from 94.76 in the prior quarter.
- The five-year high for Times Interest Earned was 8.82 in Q3 2024, with the low at 1103.5 in Q2 2026.
- Average Times Interest Earned over 5 years is 88.95, with a median of 13.44 recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: Times Interest Earned jumped 81.62% in 2022, then tumbled 9112.47% in 2026.
- Over 5 years, Times Interest Earned stood at 24.31 in 2022, then surged by 57.37% to 10.37 in 2023, then dropped by 28.38% to 13.31 in 2024, then tumbled by 84.83% to 24.6 in 2025, then plunged by 4386.4% to 1103.5 in 2026.
- The last three Times Interest Earned figures came in at 1103.5 (Q2 2026), 94.76 (Q1 2026), and 24.6 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | -1,103.50 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,103.50 |
| Mar 31, 2026 | -94.76 |
| Dec 31, 2025 | -24.60 |
| Sep 30, 2025 | -10.01 |
| Jun 30, 2025 | -11.98 |
| Mar 31, 2025 | -12.74 |
| Dec 31, 2024 | -13.31 |
| Sep 30, 2024 | -8.82 |
| Jun 30, 2024 | -9.82 |
| Mar 31, 2024 | -10.85 |
| Dec 31, 2023 | -10.37 |
| Sep 30, 2023 | -13.57 |
| Jun 30, 2023 | -14.45 |
| Mar 31, 2023 | -13.68 |
| Dec 31, 2022 | -24.31 |
| Sep 30, 2022 | -46.43 |
| Dec 31, 2021 | 13,362.00 |
| Sep 30, 2021 | -252.55 |
| Jun 30, 2021 | -31.11 |
| Mar 31, 2021 | -27.65 |